1. Continuous treatment in Finland
Martta Forsell, the Finnish Focal Point
10/11/2018
Martta Forsell

2. Data collection in Finland
Voluntary for the treatment centers
Separate client questionnaire, not (yet) part of electronic patient record.
When entering treatment
If client continues in treatment, new questionnaire in January (or springtime..)
Covers an estimated one third of the drug-related treatment
In 2012, 85 units providing drug-related treatment participated in the information collecting, submitting data on 2,688 clients.
No obvious biases
10/11/2018
Esityksen nimi / Tekijä

3. Finnish National Treatment Data 2012 (n= 2 688)
our method and the key concerns we have. 10 minutes, 5 slides. How does that sound?
10/11/2018
Martta Forsell

4. Finnish National Treatment Data 2012 (n= 2 688)
10/11/2018
Esityksen nimi / Tekijä

5. Finnish National Treatment Data 2012
10/11/2018
Esityksen nimi / Tekijä

6. Esityksen nimi / Tekijä
Length of the treatment (in years since start of treatment) on continuous treatment
10/11/2018
Esityksen nimi / Tekijä

7. Esityksen nimi / Tekijä
Length of the treatment as ‘episodes’ (columns) and the OST for clients (black)
10/11/2018
Esityksen nimi / Tekijä

8. Renewed questionnaire 2014 onwards
The Finnish survey and guidelines needed improving + TDI 3.0
The questionnaire has been revised and fully renewed questionnaire will be implemented 2014.
Will be 100% TDI 3.0 compatible
Rethinking on (among others)
‘primary drug’ on continuous treatment
Continuous treatment in an in-patient facility
OST information
More ‘re-launch’ than ‘fine-tuning’. Overall aims:
better data quality
better coverage
better understanding of the coverage
10/11/2018
Esityksen nimi / Tekijä

9. Esityksen nimi / Tekijä
Primary drug
Defining the primary drug at the start of treatment is straight forward enough
But on continuous treatment the primary problem can change
10/11/2018
Esityksen nimi / Tekijä

10. Esityksen nimi / Tekijä
THEN
NOW
Primary drug?
Primary drug?
Secondary drug?
Route of admistration?
Frequency?
Intrest on treatment inputs
Intrest on epidemiology
10/11/2018
Esityksen nimi / Tekijä

11. Primary drug Secondary drug - route -frequency
THEN
NOW
Primary drug Secondary drug - route frequency
Primary & secondary drug
Route
Frequency
10/11/2018
Esityksen nimi / Tekijä

12. Primary (secondary) drug in Finland from 2014 onwards
Primary drug now (~30 days prior entering treatment) OR
Long-standing problem drug which
contributed to the entering treatment or
is emphasized in the current treatment
~ drug the client is addicted to (whether at the moment active drug use)
The OST clients are always addicted > opioid as long-standing drug
Frequency is always the very last 30 days (except in-patient..)
10/11/2018
Esityksen nimi / Tekijä

13. Esityksen nimi / Tekijä
In-patient client
Enters treatment 1.Dec
Questionnaire: use of drugs in Nov
New questionnaire in Jan: use of drugs in Nov
> the copy of previous questionnaire
Client checks out in Feb
New questionnaire in Feb in an out-patient facility: use of drugs in Jan-Feb
10/11/2018
Esityksen nimi / Tekijä

14. Primary (secondary) drug in Finland from 2014 onwards
Primary drug now (~30 days prior entering treatment) OR
Long-standing problem drug which
contributed to the entering treatment or
is emphasized in the current treatment
~ drug the client is addicted to (whether at the moment active drug use)
The OST clients are always addicted > opioid as long-standing drug
Frequency is always the very last 30 days (except in-patient..)
NO more in-patient continuous questionnaire
10/11/2018
Esityksen nimi / Tekijä

15. Primary (secondary) drug in Finland from 2014 onwards
Primary drug now (~30 days prior entering treatment) OR
Long-standing problem drug which
contributed to the entering treatment or
is emphasized in the current treatment
~ drug the client is addicted to (whether in remiss or not)
Which we should put forward as we report the primary drug for the EMCDDA?
10/11/2018
Esityksen nimi / Tekijä